J.P. Morgan Reiterates Human Genome Sciences OW Rating

J.P. Morgan reiterates its OW rating on Human Genome Sciences, Inc.

following the positive FDA panel that overwhelmingly recommended the approval of Benlysta for systemic lupus. “As we had speculated, the drug's safety profile and the disease's unmet medical need ultimately won out in the end,” J.P. Morgan writes. “We review our real-time panel thoughts, published throughout the day, in the body of this note, but below we focus more on where we go from here and on our take heading into the Dec 9th PDUFA.” Human Genome Sciences currently trades at $24.20.